Last year proved to be a disappointment for Illumina (NASDAQ: ILMN) investors. Although the genomic-sequencing pioneer's shares rose by nearly 11%, it badly underperformed the S&P 500 index. Illumina started off 2020 with bad news as well by throwing in the towel on its planned acquisition of Pacific Biosciences of California because of regulatory obstacles.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,